Amount Raised
$10 Million
Round Type
series a
Description
IgGenix, Inc, today announced it completed a $10 million Series A financing. The financing was led by Khosla Ventures with participation from Parker Ventures and will be used to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies and other severe allergic conditions.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech